Chas Pulido

Stealth - Healthcare AI

Lyric Bio, Inc. is on a mission to reshape the global supply of life-saving medicines with its next-generation biomanufacturing platform. Every year, thousands of patients with immune deficiencies and neurological disorders rely on intravenous immunoglobulin (IvIg), but supply remains critically limited—often falling short of growing needs. The global IvIg market is already valued at over $20 billion and is projected to see strong growth as both diagnosis rates and clinical indications rise. Yet, traditional plasma-derived processes cannot keep pace, leaving patients and clinicians facing persistent shortages. Lyric Bio stands at the forefront of this market opportunity, unlocking scalable, efficient production technology to break through the bottlenecks that have long constrained access. For patients, Lyric Bio’s innovation means hope—offering the promise of consistent, reliable access to high-quality therapies. By reimagining how essential biologics like IvIg are made, Lyric Bio is delivering groundbreaking technology that will enable first in vitro production other donor derived complex therapeutics such as stem cells and red blood cells.

We are building the technology and industrial base to make the promise of cell-based regenerative medicine available to everyone, for every ailment.

Genyros SIdewinder technology leverages the convergence of AI-driven DNA design and DNA construction at scale, all the way up to whole genomes, to turn DNA into a predictive and programmable engineering material.

Based in Boston, MA, STRM.BIO (“storm bio”) is a pre-clinical, VC-backed biotechnology company that aims to fulfill the promise of gene therapy by leveraging extracellular vesicles (EVs) to deliver treatment directly to the patient (in vivo). Unlike viruses, EVs are natural carriers of nucleic acids and proteins with innate targeting capabilities, amenability to large scale/commercial manufacture, and low immunogenicity – which make them excellent cell messengers for gene therapies. Our proprietary EV platform is establishing a whole new class of therapeutics, yielding new therapies and making existing ones more effective. At STRM.BIO, we believe that our work has the potential to democratize gene therapy and bring hope for patients fighting rare diseases worldwide. We are currently recruiting team members who can help us make our vision a life-saving reality.

Accelerating molecular discovery through the power of Chemputation.

Cytosolix is a private, early stage life sciences company spun out of Yale University, developing novel oral & IV derivatives of known small molecule oncology drugs that selectively target cancer cells via a universal biomarker of solid tumors - acidity.

Strand was founded by biological engineers working together at the Massachusetts Institute of Technology (MIT). Building on the idea of creating smart therapies capable of making sophisticated decisions, they sought to apply this concept to the emerging field of mRNA therapeutics. This area was previously untapped by traditional synthetic biology, leading us to build our very own mRNA programming language, creating the world’s first platform for mRNA smart therapies. Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body via mRNA-encoded logic circuits. These circuits have the ability to implement cell-type specific expressions by sensing and classifying the unique mRNA expression signatures of cells and control the dosage of protein expression through responses to exogenously administered small molecules.

We are building the largest longitudinal cohort in the Americas to power precision health at scale for all. Our goal is to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. We are focused on Latin America and our diaspora populations throughout the world including founder populations in the Americas, those who identify as Hispanic/Latino, Black or African American, Asian American, American Indian/Alaska Native, First Nations, and Native Hawaiian/Pacific Islander as well as people who self identify as belonging to two or more of these groups. Core to our mission is building trust with the communities we serve and long term partnerships with communities, researchers, clinicians, and most of all patients and their families. This is your biobank and for the benefit of all. If we build it, we can decide how the data are used. And no one is going to do it for us, so let’s roll up our sleeves and “time to build.” Join us! Este biobanco es tuyo y para todo el continente porque si lo construimos juntos podemos decidir cómo se usan los datos y con que fines. Nadie lo va a hacer por nosotros así que bienvenido a nuestro esfuerzo. Unete!

Endpoint Health is a Precision-First therapeutics company dedicated to addressing unmet needs in immune-mediated chronic and acute diseases. We leverage our proprietary artificial intelligence (AI) platform and combine companion diagnostics with therapeutics to develop precision therapies. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.

Basil Systems is the leading AI-powered product lifecycle intelligence platform helping pharmaceutical and med-tech companies accelerate market entry, react rapidly to risk, and optimize product innovation strategies. Life science innovators leverage Basil’s advanced SaaS solution powered by BasilLink, the largest real-time global dataset of regulatory filings, submission packages, labels, clinical trials, adverse event reports, guidances, and beyond – delivering valuable insights and analytics for regulatory, quality, and commercial teams. Trusted by industry leaders, Basil Systems transforms complex data into actionable intelligence for faster, smarter, and more profitable decision making.

Mythic Therapeutics is a product-platform company that is pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Our technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. At Mythic, we focus on patient-centered science and are driven to leave a lasting impact on cancer care.

High throughput engineering of cell lines to enhance the design and manufacture of next-generation therapeutics.

Clora is an intelligent platform that matches life science companies with flexible, on-demand expertise. Clora is faster, more cost-efficient, and yields higher quality on-demand talent compared to traditional recruitment methods. Clora has access to the entire global network of life science consultants, with decades of combined industry experience across dozens of roles from companies like Merck, Johnson & Johnson, Pfizer, Novartis, and the FDA. Clora was built by industry veterans who have experienced firsthand the pain and costs associated with staffing projects with the right talent. With Clora, you simply post a project, identifying your unique requirements and our proprietary technology will select up to 3 candidates that meet the specific needs of your project. We have a 100% success rate in matching candidates to projects, within days. Posting a project only takes minutes and is risk free. Post a project today.

Stealth - Healthcare AI

Lyric Bio, Inc. is on a mission to reshape the global supply of life-saving medicines with its next-generation biomanufacturing platform. Every year, thousands of patients with immune deficiencies and neurological disorders rely on intravenous immunoglobulin (IvIg), but supply remains critically limited—often falling short of growing needs. The global IvIg market is already valued at over $20 billion and is projected to see strong growth as both diagnosis rates and clinical indications rise. Yet, traditional plasma-derived processes cannot keep pace, leaving patients and clinicians facing persistent shortages. Lyric Bio stands at the forefront of this market opportunity, unlocking scalable, efficient production technology to break through the bottlenecks that have long constrained access. For patients, Lyric Bio’s innovation means hope—offering the promise of consistent, reliable access to high-quality therapies. By reimagining how essential biologics like IvIg are made, Lyric Bio is delivering groundbreaking technology that will enable first in vitro production other donor derived complex therapeutics such as stem cells and red blood cells.

We are building the technology and industrial base to make the promise of cell-based regenerative medicine available to everyone, for every ailment.

Genyros SIdewinder technology leverages the convergence of AI-driven DNA design and DNA construction at scale, all the way up to whole genomes, to turn DNA into a predictive and programmable engineering material.